Application And Research Progress of T Cells in Immunotherapy in Cancer Treatment
DOI:
https://doi.org/10.54097/9cc6je73Keywords:
Chimeric Antigen Receptor T-cell therapy; cancer treatment; immunotherapy.Abstract
Chimeric Antigen Receptor T-cell therapy (CAR-T) has emerged as a revolutionary approach in cancer treatment, offering hope to patients with previously untreatable malignancies. This review paper provides a comprehensive overview of CART therapy, covering its structure, working mechanism, clinical applications, and strategies to mitigate adverse effects. Firstly, we delve into the structural intricacies of CAR-T cells, exploring how they are genetically engineered to express chimeric antigen receptors that enable them to target specific tumor-associated antigens. The paper elucidates the mechanisms by which CAR-T cells recognize and eliminate cancer cells, including the activation of immune responses and the production of cytokines. Next, we present an in-depth analysis of CAR-T cell therapy in clinical practice, highlighting its remarkable successes in treating various hematological malignancies and solid tumors. The review discusses the challenges associated with manufacturing, patient selection, and long-term persistence of CAR-T cells in vivo. Finally, we address the adverse effects associated with CAR-T therapy, such as cytokine release syndrome and neurotoxicity, and propose strategies to mitigate these side effects. These include the use of pharmacological interventions, patient monitoring, and the development of novel CAR-T cell constructs with improved safety profiles. In summary, this review paper provides a comprehensive and up-to-date perspective on CAR-T cell therapy, emphasizing its potential to transform the landscape of cancer treatment while addressing the challenges and risks that accompany this groundbreaking approach.
Downloads
References
S. Stoiber, B.L. Cadilha, M.R. Benmebarek, S. Lesch, S. Endres, S. Kobold, Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy, Cells 8(5) (2019).
R.E. Bird, K.D. Hardman, J.W. Jacobson, S. Johnson, B.M. Kaufman, S.-M. Lee, T. Lee, S.H. Pope, G.S. Riordan, M. Whitlow, Single-chain antigen-binding proteins, Science 242(4877) (1988) 423-426.
A.D. Posey, R.D. Schwab, A.C. Boesteanu, C. Steentoft, U. Mandel, B. Engels, J.D. Stone, T.D. Madsen, K. Schreiber, K.M. Haines, Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma, Immunity 44(6) (2016) 1444-1454.
M.V. Maus, A.R. Haas, G.L. Beatty, S.M. Albelda, B.L. Levine, X. Liu, Y. Zhao, M. Kalos, C.H. June, T cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer immunology research 1(1) (2013) 26-31.
S.E. James, P.D. Greenberg, M.C. Jensen, Y. Lin, J. Wang, B.G. Till, A.A. Raubitschek, S.J. Forman, O.W. Press, Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane, The Journal of Immunology 180(10) (2008) 7028-7038.
T. Zhang, M.-R. Wu, C.L. Sentman, An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo, The Journal of Immunology 189(5) (2012) 2290-2299.
B. Blom, H. Spits, Development of human lymphoid cells, Annu Rev Immunol 24 (2006) 287-320.
K.M. Cappell, J.N. Kochenderfer, Long-term outcomes following CAR T cell therapy: what we know so far, Nat Rev Clin Oncol 20(6) (2023) 359-371.
E.A. Chong, M. Ruella, S.J. Schuster, Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy, New England Journal of Medicine 384(7) (2021) 673-674.
S. Wang, X. Wang, C. Ye, H. Cheng, M. Shi, W. Chen, K. Qi, G. Wang, Q. Wu, L. Zeng, Z. Li, G. Jing, J. Zheng, K. Xu, J. Cao, Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia, Am J Hematol 96(5) (2021) E162-e165.
N.N. Shah, D.W. Lee, B. Yates, C.M. Yuan, H. Shalabi, S. Martin, P.L. Wolters, S.M. Steinberg, E.H. Baker, C.P. Delbrook, M. Stetler-Stevenson, T.J. Fry, D.F. Stroncek, C.L. Mackall, Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL, J Clin Oncol 39(15) (2021) 1650-1659.
S.L. Maude, N. Frey, P.A. Shaw, R. Aplenc, D.M. Barrett, N.J. Bunin, A. Chew, V.E. Gonzalez, Z. Zheng, S.F. Lacey, Chimeric antigen receptor T cells for sustained remissions in leukemia, New England Journal of Medicine 371(16) (2014) 1507-1517.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Highlights in Science, Engineering and Technology

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







